10-Q: PetVivo Holdings Reports Q3 2024 Results, Revenue Up but Losses Persist

PetVivo Holdings, Inc. reports increased revenue for the third quarter of 2024, but continues to experience net losses and working capital challenges.

Summary

• PetVivo Holdings, Inc. reported a net loss of $1.75 million for the three months ended December 31, 2023, compared to a net loss of $2.31 million for the same period in 2022.
• The company's revenue increased to $595,891 for the quarter, up from $510,109 in the prior year, primarily driven by sales of its Spryng product.
• Operating expenses were $2.55 million for the quarter, slightly down from $2.61 million in the same period last year.
• For the nine months ended December 31, 2023, the net loss was $8.3 million, compared to $6.39 million in the same period of 2022.
• The company's revenue for the nine-month period was $920,440, up from $791,563 in the prior year.
• PetVivo's working capital deficit was $169,236 as of December 31, 2023, with current assets of $1.49 million and current liabilities of $1.66 million.
• The company has an accumulated deficit of $80.15 million as of December 31, 2023.
• PetVivo is dependent on raising additional capital to fund its operations and commercialization efforts.

Sentiment

Score: 4

Explanation: The document shows some positive signs with increased revenue and a reduction in net loss for the quarter, but the company's continued losses, working capital deficit, and dependence on capital raises create a negative outlook. The risk of delisting from Nasdaq further lowers the sentiment.

Positives

• Revenue increased for both the three and nine-month periods ended December 31, 2023.
• The net loss for the three months ended December 31, 2023, decreased compared to the same period in 2022.
• The company extinguished $385,874 of payables, improving the balance sheet.
• PetVivo secured a new distribution agreement with Covetrus, expanding its sales channels.
• The company raised $1,248,000 through a private offering in February 2024.

Negatives

• The company continues to experience significant net losses.
• PetVivo has a working capital deficit of $169,236 as of December 31, 2023.
• The company has an accumulated deficit of $80.15 million.
• Operating expenses remain high, impacting profitability.
• The company is dependent on raising additional capital to fund its operations.

Risks

• The company's ability to continue as a going concern is dependent on its ability to achieve profitability and/or obtain adequate financing.
• PetVivo is subject to the risk of not meeting the continued listing requirements of The Nasdaq Capital Market.
• The company faces risks related to the commercialization of its products and the need for additional capital.
• There is no guarantee that the company will be successful in raising additional capital to fund its business plan.
• The company is subject to risks related to legal proceedings.

Future Outlook

The company expects to continue to raise additional capital through the sale of its securities to fund its business expansion. The company anticipates completing a clinical study with Colorado State University in March 2024 and two canine clinical studies with Ethos Veterinary Health in October 2023 and October 2024.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern.
• Management believes that the increased revenues and margins provided by Spryng will accelerate its adoption rate and propel it forward as the standard of care for canine and equine lameness related to or due to synovial joint issues.

Industry Context

The company operates in the veterinary market, which is characterized by a growing demand for innovative treatments for companion animals. The company's Spryng product is positioned as an alternative to traditional treatments for osteoarthritis in dogs and horses, addressing the underlying causes of the condition rather than just the symptoms. The company's move to non-exclusive distribution agreements is consistent with a strategy to expand market reach and sales channels.

Comparison to Industry Standards

• PetVivo's revenue growth is positive, but the company's continued losses are a concern compared to established players in the veterinary pharmaceutical and medical device industry.
• The company's reliance on capital raises to fund operations is not uncommon for early-stage biotech companies, but it highlights the need for a clear path to profitability.
• The company's distribution agreements with MWI and Covetrus are similar to strategies used by other companies in the industry to expand market reach.
• The company's focus on clinical studies is consistent with industry standards for demonstrating the safety and efficacy of veterinary medical devices.
• The company's product, Spryng, is positioned to compete with existing treatments for osteoarthritis, such as NSAIDs and steroid injections, by offering a more targeted approach to joint health.

Legal Proceedings

• David Masters, a former employee, board member, and consultant to the Company, has threatened to file suit against the Company to recover in excess of $2 million. The company settled this claim for $180,000.

Stakeholder Impact

• Shareholders face the risk of potential delisting from Nasdaq and dilution from future capital raises.
• Employees may be impacted by the company's financial instability and dependence on additional funding.
• Customers (veterinarians) may benefit from the company's products, but the company's financial health could impact product availability.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to complete a clinical study with Colorado State University in March 2024.
• The company will continue to pursue two canine clinical studies with Ethos Veterinary Health.
• The company will focus on expanding its distribution outlets.
• The company will continue to raise additional capital to fund its operations.

Key Dates

Keywords

PetVivo, Spryng, veterinary, biomaterials, osteoarthritis, distribution, revenue, net loss, capital raise, medical device